Diltiazem Market Size, Share & Growth Analysis by 2028
地尔硫卓市场规模预计将从 2021 年的 3.6995 亿美元增至 2028 年的 8.3252 亿美元;预计 2021 年至 2028 年的复合年增长率为 12.3%。
心血管疾病发病率上升、老龄人口增加等因素推动了市场的增长。然而,地尔硫卓的副作用可能会阻碍市场的增长。
心脏病多见于老年人,因为他们免疫力较弱,其他健康问题也较严重。一般的衰老因素会导致心脏和血管变硬,从而引发心脏疾病。随着年龄的增长,收缩压也会升高,并可能导致心血管疾病。因此,高血压是 75 岁及以上人群心脏病的常见原因。其次是冠状动脉疾病和心力衰竭。尽管心律失常的发病率涵盖所有年龄段的人,但老年人的发病率显著上升。
根据《2019 年全球老龄化》调查,2019 年全球 65 岁及以上人口总数为 7.03 亿。到 2050 年,老年人口预计将翻一番,达到 15 亿。到 2025 年,65 岁及以上人口的发病率可能会从 2019 年的每 11 人中 1 人增加到每 6 人中 1 人。这一人群更容易患心血管疾病,例如心律失常。同样,根据世界卫生组织的数据,到 2050 年,60 岁及以上人口的比例预计将从 2015 年的 12% 达到 22%。根据联邦老龄化相关统计机构间论坛的报告《2016 年美国老年人:幸福感的关键指标》,35.8% 的 85 岁及以上人士患有轻度或极度认知障碍。此外,根据联合国《2017年世界人口老龄化报告》,2017年全球60岁及以上人口为9.62亿,预计到2050年这一数字将达到近21亿。
根据美国人口普查局的数据,到 2060 年,美国 65 岁及以上人口的数量预计将从 2016 年的 4600 万增加一倍以上,达到 9800 多万,65 岁及以上年龄组占全球人口的约 24%,高于 2016 年的 15%。2017 年,欧盟 60 岁及以上人口比例最高(25%)。世界其他地区也正在经历人口老龄化,到 2050 年,除非洲外,世界所有地区 60 岁及以上人口的比例都将达到约四分之一或更多。预计到 2030 年,世界老年人口将达到 14 亿美元,到 2050 年将达到 21 亿美元,到 2100 年将超过 31 亿美元。老年人口更容易出现异常表现、合并症和不良后果。与衰老相关的心血管系统结构和功能变化是心血管疾病的主要原因。因此,世界老年人口的增加导致心血管疾病发病率的增加,从而促进了地尔硫卓市场的增长
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
地尔硫卓市场:
复合年增长率(2021 - 2028 年)12.3%- 2021 年市场规模
3.6995 亿美元 - 2028 年市场规模
8.3251 亿美元
市场动态
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
关键人物;主力;重要一员
- 博士伦健康
- 梯瓦制药工业有限公司
- 迈兰公司
- 雅典娜
- 辉瑞公司
- 格兰马克
- 山德士(诺华公司)
- 太阳药业有限公司
- 希克玛制药公司
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 药片
- 胶囊
- 注射
- 心绞痛
- 高血压
- 其他的
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
市场洞察
心血管疾病发病率上升
地尔硫卓是一种钙通道阻滞剂。它能降低心率,放松身体和心脏的血管。血液流动更顺畅,心脏泵血所需的力气也更小。地尔硫卓通过降低心率、血压和心脏收缩力来降低心肌需氧量,也是治疗稳定型慢性心绞痛的良好替代药物。地尔硫卓对血管平滑肌、心室心肌和特殊传导组织有强大的心血管作用。在心室功能正常的个体中,它会引起冠状动脉和外周血管扩张,具有负性变时性和变传导性影响,并且几乎没有负性肌力作用。地尔硫卓在多种心血管疾病中都有潜在用途。它在缓解与变异型心绞痛相关的冠状动脉痉挛方面非常有效。与患有劳力性心绞痛的硝酸盐相比,地尔硫卓具有相似的疗效。
根据世界卫生组织的数据,心血管疾病 (CVD) 是全球第一大死亡原因。心血管疾病是发病的主要原因,影响的人数比任何其他疾病都要多。一些心血管疾病是脑血管病、冠心病和风湿性心脏病。吸烟、不健康饮食和缺乏运动是增加心脏病发作和中风风险的主要生活方式因素。此外,其他可能导致心血管疾病的风险因素包括高血压、糖尿病和胆固醇水平升高。
心房颤动 (AFib)是最常见的心脏病类型,心跳过快、过慢或不规律。疾病控制和预防中心 (CDC) 估计,美国有 270 万至 610 万人患有 AFib。2017 年,约有 166,793 张死亡证明提到了 AFib,并且是 26,077 例死亡的主要原因。据报道,美国每年有超过 454,000 人因 AFib 住院,约有 158,000 人死亡。
此外,欧洲心脏病学会报告称,心房颤动是最常见的心律失常,占欧洲国家医疗支出的 0.28% 至 2.6%。它还提到,患有心房颤动的患者患中风的风险高出五倍。欧洲 20% 至 30% 的中风是由于心房颤动引起的。根据欧洲心脏病学会在 2016 年进行的研究,欧盟约有 760 万 65 岁及以上的人患有心房颤动。欧洲心脏病学会估计,到 2060 年,这一数字预计将增加 89%,约有 1440 万人将患有心房颤动。此外,预计到 2060 年患病率将达到 9.5%,目前为 7.8%。
此外,亚太地区房颤的患病率也在上升。根据Biosense Webster 2019年发布的报告《超越负担:房颤对亚太地区的影响》,亚太地区有超过1600万人患有房颤,影响到中老年人口。该报告还估计,到2050年,这一数字将达到约7200万人。
亚太地区房颤患病率(按国家/地区)
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
来源:Biosense Webster 报告:超越负担:心房颤动对亚太地区的影响
钙通道阻滞剂地尔硫卓 (Cardizem) 和维拉帕米 (Calan 和 Isoptin) 对心房颤动患者的初始心室率控制有效。这些药物以推注剂量静脉注射,直到心室率变慢。此外,地尔硫卓可降低房室结的传导,这对心房颤动患者的心率控制也很有用。因此,全球心房颤动患病率的不断上升推动了地尔硫卓市场的增长。
基于产品类型的洞察
根据产品类型,市场分为胶囊、注射剂和片剂。2021 年,片剂占据了最大的市场份额,而胶囊剂预计在 2021 年至 2028 年期间将出现最快的复合年增长率。
基于应用的洞察
根据应用,市场细分为心绞痛、高血压和其他。 2021 年,高血压细分市场占据了最大的市场份额,而心绞痛细分市场预计在未来几年将以最快的复合年增长率增长。
在地尔硫卓市场运营的公司强调采用产品创新战略来满足全球不断变化的客户需求,这也使他们能够在全球市场上保持自己的品牌名称。
地尔硫卓市场报告范围
报告属性 | 细节 |
---|---|
2021 年市场规模 | 3.6995亿美元 |
2028 年市场规模 | 8.3251亿美元 |
全球复合年增长率(2021 - 2028) | 12.3% |
历史数据 | 2019-2020 |
预测期 | 2022-2028 |
涵盖的领域 | 按产品类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
地尔硫卓市场 – 细分
按产品类型
- 药片
- 胶囊
- 注射
按应用
- 高血压
- 心绞痛
- 其他的
地尔硫卓市场—按地区划分
- 北美
- 我们
- 加拿大
- 墨西哥
- 欧洲
- 法国
- 德国
- 意大利
- 英国
- 西班牙
- 欧洲其他地区
- 亚太地区 (APAC)
- 中国
- 印度
- 韩国
- 日本
- 澳大利亚
- 亚太地区其他地区
- 中东和非洲 (MEA)
- 南非
- 沙特阿拉伯
- 阿联酋
- MEA 其他地区
- 南美洲和中美洲(SCAM)
- 巴西
- 阿根廷
- 其余的骗局
公司简介
- 博士伦健康
- 梯瓦制药工业有限公司
- 迈兰公司
- 雅典娜
- 辉瑞公司
- 格兰马克
- 山德士(诺华公司)
- 太阳药业有限公司
- 希克玛制药公司
- Zydus 制药公司
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Asia Pacific is expected to be the fastest-growing region and is likely to expand at a high growth rate due to government initiatives in drug approval process. Moreover, the rise in prevalence of cardiovascular disease such as angina, hypertension and arrythmia is likely to boost the growth of market in Asia-Pacific region. For instance, The rise in the cardiovascular diseases is observed due to the rise in the risk factors such as smoking, blood pressure, cholesterol and diabetes. The percentage of men who smoke in Japan is approximately 35.4% which is nearly double than the rate of smoking in US. The average blood pressure in Japan is nearly 130.5 and the cholesterol leverage averages approximately 201 mg/dl (5.2 mmol/L). However, the rate of diabetes is little less, compared to the rate in US. The rate of diabetes in Japan is approximately 7.2%. Owing to these factors the country is likely to demand more of the cardiovascular diagnostic and treatment devices in future.
The global diltiazem market based on product is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market, by product type. However , the capsules segment of Diltiazem Market is also expected to witness fastest CAGR of 12.8% during 2021 to 2028. Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.
The Diltiazem market majorly consists of the players such as Bausch Health, Teva Pharmaceutical Industries Ltd, Mylan N.V, Athenex, Pfizer, Inc, Glenmark, Sandoz (Novartis Ag),Sun Pharmaceutical Company Ltd, Hikma Pharmaceuticals, Zydus Pharmaceuticals among others amongst others.
The US is the largest market for Diltiazem at a global level., In the United States hypertension was a primary or contributing factor in roughly half a million deaths in in recent years. Hypertension-related deaths have increased by 72 percent and 20 percent in rural and urban areas of the United States, respectively. According to Centers for Disease Control and Prevention, high blood pressure costs the United States about $131 billion each year. In the United States, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. According to the WHO in the United States, one person dies from cardiovascular disease every 36 seconds. Every year, over 655,000 Americans die from heart disease, accounting for one out of every four deaths.
Diltiazem is a benzothiazepine derivative that acts as an antihypertensive and vasodilator. Diltiazem is an antihypertensive and vasodilator that lowers blood pressure by relaxing the vascular muscle. This is due to the long-term therapeutic effects of decreasing blood pressure since it lowers the risk of fatal and non-fatal cardiovascular events, such as strokes and myocardial infarction. According to in vitro binding experiments, diltiazem is 70%-80% bound to plasma proteins. 12 At clinically relevant concentrations, around 40% of the medication is thought to attach to alpha-1-glycoprotein, whereas about 30% of the drug is thought to bind to albumin.
The factors that are driving and restraining factors that will affect Diltiazem market in the coming years. Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.
The List of Companies - Diltiazem Market
- Bausch Health
- Teva Pharmaceutical Industries Ltd
- Mylan N.V
- Athenex
- Pfizer, Inc
- Glenmark
- Sandoz (Novartis Ag)
- Sun Pharmaceutical Company Ltd
- Hikma Pharmaceuticals
- Zydus Pharmaceuticals
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.